Article

Pharmacy Clinical Pearl of the Day: Immune Globulins

Immune Globulins are injections that are used to treat immunodeficiency disorders.

Clinical Pearl of the Day: Immune Globulins

Immune globulins are injections that are used to treat immunodeficiency disorders.

Explanation:

  • Part of immunizing agents
  • Made up of antibodies
  • Given intravenously and subcutaneously
  • Used when the body does not make enough antibodies
  • The antibodies from IVIG usually last for weeks to months
  • Can be given for diseases such as immune thrombocytopenia, Guillain-Barre Syndrome, and chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Examples: Gamunex, Privigen, Octagam, Gammagard, Hyqvia, Hizentra, Cuvitru

Reference:

Patient education: Intravenous immune globulin (IVIG) (Beyond the Basics) - UpToDate

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards